In Brief: Transmissible spongiform encephalopathies
This article was originally published in The Tan Sheet
Executive Summary
Transmissible spongiform encephalopathies: FDA advisory committee on transmissible spongiform encephalopathies scheduled to meet April 15-16. Discussion the first day will focus on the safety of tallow and tallow derivatives used in pharmaceuticals, cosmetics and other FDA-regulated products as well as U.S. and global issues on nonedible tallow. On April 16, the committee will discuss gelatin and dura mater products. The meeting will be held at the Holiday Inn, Bethesda, Md..